[HTML][HTML] Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem, A Mårtensson… - Malaria Journal, 2021 - Springer
Background The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
[PDF][PDF] Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem, A Mårtensson… - 2021 - academia.edu
Background: The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem… - Malaria …, 2021 - search.ebscohost.com
Background: The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem, A Mårtensson… - Malaria Journal, 2021 - go.gale.com
Background The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
[PDF][PDF] Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute‑Lau, U Morris, M Msellem, A Mårtensson… - 2021 - run.unl.pt
Background: The anti‑malarial drug, amodiaquine, a commonly used, long‑acting partner
drug in artemisinin‑based combination therapy, is metabolized to active desethyl …
drug in artemisinin‑based combination therapy, is metabolized to active desethyl …
[HTML][HTML] Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem… - Malaria …, 2021 - ncbi.nlm.nih.gov
Background The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem… - Malaria …, 2021 - search.proquest.com
Background The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem, A Mårtensson… - 2021 - cabidigitallibrary.org
Background: The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem… - Malaria …, 2021 - diva-portal.org
BACKGROUND: The anti-malarial drug, amodiaquine, a commonly used, long-acting
partner drug in artemisinin-based combination therapy, is metabolized to active desethyl …
partner drug in artemisinin-based combination therapy, is metabolized to active desethyl …
[PDF][PDF] Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute‑Lau, U Morris, M Msellem, A Mårtensson… - 2021 - scholar.archive.org
Background: The anti‑malarial drug, amodiaquine, a commonly used, long‑acting partner
drug in artemisinin‑based combination therapy, is metabolized to active desethyl …
drug in artemisinin‑based combination therapy, is metabolized to active desethyl …